Navigation Links
Paloma Pharmaceuticals to Present at the American Association for Cancer Research
Date:4/15/2008

- Presentations highlight Palomid 529 as an anti-angiogenic, anti-tumor

Akt/mTOR inhibitor -

JAMAICA PLAIN, Mass., Apr 15 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented three presentations at the 2008 annual meeting of the American Association for Cancer Research describing cancer drug Palomid 529 (P529).

P529 is a non-steroidal, synthetic, small molecule dual acting anti-angiogenic and direct anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic agent and anti-tumor agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the three presentations, "Palomid 529, a Dual Acting Anti-angiogenic and Direct Anti-tumor Agent Affecting the PI3K/Akt/mTor Pathway," was be given by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Palomid 529 (P529) inhibits tumor angiogenesis and selectively inhibits the Akt but not MAPK signaling pathways," was given by the laboratory of Dr. Laura E. Benjamin of the Department of Pathology and Center for Vascular Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. The last presentation, "Enhancement of radiotherapy in prostate cancer by the dibenzo[c]chrom-6-one derivative P529" was given by the laboratory of Dr. Alfonso Calvo of the Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.

"mTOR and the protein complexes mTORC1 and mTORC2 are excellent targets for cancer therapy because they provide important signaling links to tumor and stromal pathways dysregulated in many cancers," said Dr. Benjamin whose work has helped to understand the mechanism of action of P529.

"We have shown in a series of prost
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palomar and Q-MED AB Enter Into International Distribution Agreement
2. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
3. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
4. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
5. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
6. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Microbia Announces Name Change to Ironwood Pharmaceuticals
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Memory Pharmaceuticals Receives Nasdaq Notification
11. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY ... The Boston Area Chapter of ISPE (International Society for ... for Wed., Oct. 1 at Gillette Stadium Clubhouse in ... in ISPE Boston’s long history, with more than 375 ... , HOLLOWAY AMERICA President David Simpson is looking ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Smilodon ranks alongside Tyrannosaurus rex as the ultimate killing ... was a fearsome predator of Ice-Age America,s lost giants. ... debated how this iconic predator used its ferocious fangs ... published today in the US Proceedings of the National ...
... 1 Boston Scientific,Corporation (NYSE: BSX ) will ... quarter ended September 30, 2007 on Friday,October 19, at ... by Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, ... Chief Financial Officer. The live webcast and archived ...
... Space Center,has awarded a five-year, $120-million extension of ... Institute, also known,as NSBRI, of Houston. Under the ... continue biomedical research in support of a,long-term human ... the cooperative agreement began April 1, 1997, with,a ...
Cached Biology Technology:Scientists say sabercat bit like a pussycat 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... Calif. Beyond the personal tragedy of chronic alcoholism ... know severe alcoholism stresses the heart and that mitochondria, ... But they don,t know the precise mechanism. Now ... Center of the New York State Department of Health ...
... 22, 2012 -- The first clinical trial of a ... by the Infectious Disease Research Institute (IDRI), a Seattle-based ... diseases of poverty. The Phase 1 trial is taking ... trial planned in India, an epicenter of the disease. ...
... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
Cached Biology News:A change of heart 2First vaccine against fatal visceral leishmaniasis enters clinical trial 2First vaccine against fatal visceral leishmaniasis enters clinical trial 3Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: